Herpesviruses enhance fibrin clot lysis

Summary

The incorporation of virus- and host-derived procoagulant factors initiates clotting directly on the surface of herpesviruses, which is an explanation for their correlation to vascular disease. The virus exploits the resulting thrombin to enhance infection by modulating the host cell through protease activated receptor (PAR) 1 signalling. Prior reports demonstrated that at least one herpesvirus expresses surface annexin A2 (A2), a cofactor for tissue plasminogen activator (tPA)-dependent activation of plasminogen to plasmin. Since plasmin is both a fibrinolytic protease and PAR agonist, we investigated whether herpesviruses enhance fibrinolysis and the effect of plasmin on cell infection. Herpes simplex virus types 1 (HSV1) and 2, and cytomegalovirus (CMV) purified from various cell lines each accelerated the proteolytic activation of plasminogen to plasmin by tPA. Ligand blots identified A2 as one of several plasminogen binding partners associated with the virus when compared to an A2-deficient virus. This was confirmed with inhibitory A2-antibodies. However, A2 was not required for virus-enhanced plasmin generation. HSV1, HSV2 and CMV accelerated tPA-dependent fibrin clot lysis by up to 2.8-fold. Modest plasmin generation and fibrinolysis was detected independent of exogenous tPA, which was inhibited by plasminogen activator inhibitor type-1 and ε-aminocaproic acid; however, the molecular basis remains speculative. Up to a ∼6-fold enhancement of infection was provided by plasmin-mediated cell infection. Inhibitory antibodies revealed that plasmin increased HSV1 infection through a mechanism involving PAR2. Thus, virus-enhanced fibrinolysis may help explain the paradox of the highly procoagulant in vitro herpesvirus surface eliciting only relatively weak independent vascular disease risk.

Keywords

Fibrinolysis - herpes simplex virus - cytomegalovirus - tissue plasminogen activator - plasmin

• References

• 1 Sutherland MR, Raynor CM, Leenknegt H. et al. Coagulation initiated on herpesviruses. Proc Natl Acad Sci USA 94: 13510-13514.
• 2 Gershom ES, Sutherland MR, Lollar P. et al. Involvement of the contact phase and intrinsic pathway in herpes simplex virus-initiated plasma coagulation. J Thromb Haemost 2010; 08: 1037-1043.
• 3 Sutherland MR, Friedman HM, Pryzdial ELG. Herpes simplex virus type 1-encoded glcoprotein C enhances coagulation factor VIIa activity on the virus. Thromb Haemost 2004; 92: 947-955.
• 4 Etingin OR, Silverstein RL, Friedman HM. et al. Viral activation of the coagulation cascade: Molecular interaction at the surface of infected endothelial cells. Cell 1990; 61: 657-662.
• 5 Sutherland MR, Friedman HM, Pryzdial ELG. Thrombin enhances herpes simplex virus infection of cells involving protease-activated receptor 1. J Thromb Haemost 2007; 05: 1055-1061.
• 6 Wright JF, Kurosky A, Pryzdial ELG. et al. Host cellular protein annexin II is associated with cytomegalovirus particles isolated from cultured human fibroblasts. J Virol 1995; 69: 4784-4791.
• 7 Raynor CM, Wright JF, Waisman DM. et al. Annexin II enhances cytomegalovirus binding and fusion to phospholipid membranes. Biochem 1999; 38: 5089-5095.
• 8 Collen D. On the Regulation and Control of Fibrinolysis. Thromb Haemost 1980; 43: 77-89.
• 9 Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/ tissue plasminogen activator: identity with annexin II. J Biol Chem 1994; 269: 21191-21197.
• 10 Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen/tissue plasminogen activator: Annexin II-mediated enhancement of tPA-dependent plasminogen activation. J Biol Chem 1994; 269: 21198-21203.
• 11 Majumandar M, Tarui T, Shi B. et al. Plasmin-induced migration requires signaling through protease receptor 1 and integrin alpha9 beta1. J Biol Chem 2004; 279: 37528-37534.
• 12 Laumonnier Y, Syrovets T, Burysek B. et al. Identification of the annexin A2 heterotetramer as a receptor for the plasmin-induced signaling in human peripheal monocytes. Blood 2006; 107: 3342-3349.
• 13 Friedman HM, Wang L, Fishman NO. et al. Immune evasion of herpes simplex virus type 1 glycoprotein gC. J Virol 1996; 70: 4253-4260.
• 14 Pryzdial ELG, Wright JF. Prothrombinase assembly on an enveloped virus: evidence that the cytomegalovirus surface contains procoagulant phospholipid. Blood 1994; 84: 3749-3757.
• 15 Talbot K, Meixner SC, Pryzdial ELG. Enhanced fibrinolysis by proteolysed coagulation factor Xa. Biochem Biophys Acta 2010; 1804: 723-730.
• 16 Fleury V, Loyau S, Lijnen HR. et al. Molecular Assembly of Plasminogen and Tissue-Type Plasminogen-Activator on An Evolving Fibrin Surface. Eur J Biochem 1993; 216: 549-556.
• 17 Hajjar KA, Hamel NM, Harpel PC. et al. Binding of plasminogen to cultured human endothelial cells. J Clin Inv 1987; 80: 1712-1719.
• 18 Hajjar KA. Cellular receptors in the regulation of plasmin generation. Thromb Haemost 1995; 74: 294-301.
• 19 Collen DH, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-3124.
• 20 LeBouder F, Morello E, Rimmelzwaan GF. et al. Annexin II incorporated into influenza virus particles supports virus replication by converting plasminogen into plasmin. J Virol 2008; 82: 6820-6828.
• 21 Monroy V, Ruiz BH. Participation of the dengue virus in the fibrinolytic process. Virus Genes 2000; 21: 197-208.
• 22 Degen JL, Bugge TH, Goguen JD. Fibrin and fibrinolysis in infection and host defense. J Thromb Haemost 2007; 05: 24-31.
• 23 Nicholson AC, Hajjar DP. Herpesviruses in atherosclerosis and thrombosis - Etiologic agents or ubiquitous bystanders. Arterioscl Throm Vas 1998; 18: 339-348.
• 24 Cesarman-Maus G, Hajjar KA. Molecular mechansims of fibrinolysis. Brit J Haematol 2005; 129: 307-321.
• 25 Kwon M, MacLeod TJ, Zhang Y. et al. S100A10, annexin A2 and annexin A2 heterotetramer as candidate plasminogen receptors. Frontiers Biosci 2005; 10: 300-325.
• 26 Derry MC, Sutherland MR, Restall CM. et al. Annexin 2-mediated enhancement of cytomegalovirus infection opposes inhibition by annexin 1 or annexin 5. J Gen Virol 2007; 88: 19-27.
• 27 Ryzhova EV, Vos RM, Albright AV. et al. Annexin 2: A novel human immunodeficiency virus type 1 Gag binding protein involved in replication in monocyte-derived macrophages. J Virol 2006; 80: 2694-2704.
• 28 Gonzalez-Reyes S, Garcia-Manso A, del Barrio G. et al. Role of annexin A2 in cellular entry of rabbit vesivirus. J Gen Virol 2009; 90: 2724-2730.
• 29 Kuliopulos A, Covic L, Seeley SK. et al. Plasmin desensitization of the PARI thrombin receptor: Kinetics, sites of truncation, and implications for thrombolytic therapy. Biochem 1999; 38: 4572-4585.
• 30 Quinton TM, Kim S, Derian CK. et al. Plasmin-mediated activation of platelets occurs by cleavage of protease-activated receptor 4. J Biol Chem 2004; 279: 18434-18439.
• 31 Peterson EA, Sutherland MR, Nesheim ME. et al. Thrombin induces endothelial cell surface exposure of the plasminogen receptor annexin 2. J Cell Sci 2003; 116: 2399-2408.
• 32 Lijnen HR. Elements of the fibrinolytic system. Ann NY Acad Sci 2001; 936: 226-236.
• 33 Melnick JL, Schattner A. Viruses and Atherosclerosis. Isr J Med Sci 1992; 28: 463-465.
• 34 Melnick JL, Adam E, DeBakey ME. Possible role of cytomegalovirus in atherogenesis. J Am Med Assoc 1990; 263: 2204-2207.
• 35 Vercellotti GM. Effects of viral activation of the vessel wall on inflammation and thrombosis. Blood Coag Fibrinol 1998; 09 (Suppl. 02) S3-S6.
• 36 Nicholson AC, Hajjar DP. Herpesvirus and thrombosis: activation of coagulation on the endothelium. Clin Chim Acta 1999; 286: 23-29.
• 37 Hajjar DP. Viral pathogenesis of atherosclerosis: Impact of molecular mimicry and viral genes. Am J Pathol 1991; 139: 1195-1211.
• 38 Siscovick DS, Schwartz SM, Corey L. et al. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults - The Cardiovascular Health Study. Circulation 2000; 102: 2335-2340.
• 39 Nieto FJ, Adam E, Sorlie P. et al. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical restenosis. Circulation 1996; 94: 922-927.
• 40 Pawlak K, Zolbach K, Borawski J. et al. Chronic viral hepatitis C, oxidative stress and the coagulation/fibrinolysis system in haemodialysis patients. Thromb Res 2008; 123: 166-170.
• 41 Laine O, Makela S, Mustonen J. et al. Enhanced thrombin formation and fibrinolysis during acute Puumala hantavirus infection. Thromb Res 2010; 126: 154-158.
• 42 Marchi R, Nagaswami C, Weisel JW. Fibrin formation and lysis studies in dengue virus infection. Blood Coagul Fibrin 2009; 20: 575-582.